25.60Open25.60Pre Close0 Volume2 Open Interest160.00Strike Price0.00Turnover87.06%IV-20.78%PremiumJan 17, 2025Expiry Date74.28Intrinsic Value100Multiplier12DDays to Expiry0.00Extrinsic Value100Contract SizeAmericanOptions Type0.9933Delta0.0005Gamma3.14Leverage Ratio-0.0446Theta0.0533Rho3.12Eff Leverage0.0080Vega
Alnylam Pharmaceuticals Stock Discussion
Alnylam Highlights New Data From HELIOS-B Study of Vutrisiran for the Treatment of Transthyretin Amyloidosis With Cardiomyopathy at Heart Failure Society of America Annual Scientific Meeting 2024 | ALNY Stock News
ALNY BUY ALERT 🚨 DRUG NEWS MULTIPLE PRICE TARGET RAISES
No comment yet